Novartis has announced positive topline results from ARISE, the first Phase III study evaluating the efficacy and safety of monthly...
Amgen has announced results from the head-to-head Phase III study comparing AMG 416 with cinacalcet for the treatment of secondary...
Positive Phase IIIb LIBERTY study for AMG 334 in patients with episodic migraine.
Amgen announced the submission of a Biologics License Application to the FDA for AMG 334 (erenumab) to prevent migraine. Erenumab...
Amgen has presented the findings from a head-to-head Phase III study comparing intravenous etelcalcetide (AMG 416) with oral cinacalcet (Mimpara)...
Amgen has announced that a Phase III study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary...
Amgen announced that a second placebo-controlled Phase III study evaluating AMG 416 for the treatment of secondary Hyperparathyroidism (SHPT) in...
The Phase III DESCARTES study evaluating the long-term 52-week safety and efficacy of AMG 145 (evolocumab), from Amgen, for the...
Novartis announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for AMG 334 (erenumab) for...
This guide has therefore been prepared with the important objective of providing healthcare professionals with reference information on both the science and regulation underpinning the use of biosimilars.